{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-043405","form_type":"8-K","ticker":"RAPP","cik":"0002012593","company_name":"Rapport Therapeutics, Inc.","filed_at":"2025-03-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.796137+00:00","generated_at":"2026-05-25T21:53:04.763364+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Rapport hires Dr. Jeffrey Sevigny as CMO; Phase 2a data expected Q3 2025","bullets":["Jeffrey Sevigny, former CMO at Prevail Therapeutics (Eli Lilly), appointed CMO effective immediately.","Phase 2a trial of RAP-219 in refractory focal epilepsy to report topline results in Q3 2025.","Phase 2a trial of RAP-219 in bipolar mania to initiate in Q3 2025 with data expected in H1 2027.","Sevigny brings 15+ years experience from Roche, Biogen, Novartis, and Merck to lead clinical strategy."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-043405","json":"https://secwatch.observer/filing/0001193125-25-043405.json","markdown":"https://secwatch.observer/filing/0001193125-25-043405.md","text":"https://secwatch.observer/filing/0001193125-25-043405.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2012593/000119312525043405/0001193125-25-043405-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2012593/000119312525043405/d876788d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T21:53:04.763364+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}